Howard Feldman

机构：University of California San Diego, Alzheimer’s Disease Neuroimaging Initiative · ORCID：0000-0002-9258-4538

发表论文 603 篇 · 总被引 91639 次 · h-index 105

代表论文

Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials (2026 · The Lancet · 被引 60)
Effects of exercise on cognition and Alzheimer's biomarkers in a randomized controlled trial of adults with mild cognitive impairment: The EXERT study (2025 · Alzheimer s & Dementia · 被引 27)
Pharmacokinetic and pharmacodynamic assessment of oral nicotinamide in the NEAT clinical trial for early Alzheimer’s disease (2025 · Alzheimer s Research & Therapy · 被引 14)
Effects of exercise versus usual care on older adults with amnestic mild cognitive impairment: EXERT versus ADNI (2025 · Alzheimer s & Dementia · 被引 10)
Higher Educational Attainment and Accelerated Tau Accumulation in Alzheimer Disease (2025 · JAMA Neurology · 被引 9)
Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo‐controlled trials of semaglutide in participants with early‐stage symptomatic Alzheimer's disease (2026 · Alzheimer s & Dementia Translational Research & Clinical Interventions · 被引 8)